THE Janssen Pharmaceutical Companies of Johnson & Johnson have announced the approval of Erlyand (apalutamide) by the Therapeutic Goods Administration (TGA), and its entry on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with non-metastatic, castration-resistant prostate cancer (nmCRPC).
The product was granted a priority review determination by the TGA on 17 Jan 2018 and was the first medicine to be evaluated under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium's New Chemical Entities Work Sharing Pilot.
CLICK HERE for the PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jul 18
